Kynurenine Pathway in Schizophrenia: Galantamine-Memantine Combination for Cognitive Impairments.

Authors

Maju Mathew Koola, George Washington University
Jennifer Sklar
Whitney Davis
Agnieszka Nikiforuk
John K Meissen
Aarti Sawant-Basak
Scott T Aaronson
Rouba Kozak

Document Type

Journal Article

Publication Date

3-1-2018

Journal

Schizophrenia Research

Volume

193

Inclusive Pages

459-460

DOI

10.1016/j.schres.2017.07.005

Keywords

Adolescent; Adult; Cognitive Dysfunction; Drug Therapy, Combination; Female; Galantamine; Humans; Kynurenine; Male; Memantine; Middle Aged; Neuropsychological Tests; Nootropic Agents; Retrospective Studies; Schizophrenia; Signal Transduction; Young Adult

APA Citation

Koola, M., Sklar, J., Davis, W., Nikiforuk, A., Meissen, J., Sawant-Basak, A., Aaronson, S., & Kozak, R. (2018). Kynurenine Pathway in Schizophrenia: Galantamine-Memantine Combination for Cognitive Impairments.. Schizophrenia Research, 193 (). http://dx.doi.org/10.1016/j.schres.2017.07.005

Peer Reviewed

1